Pharmacology of new hormonal therapies in the treatment of pediatric endocrine disorders.
Advances in genetic engineering will make possible treatment of many pediatric endocrine disorders with replacement therapy. Some of these conditions include short stature, precocious puberty, and diabetes mellitus. Although the availability of such hormonal replacement offers new treatment modalities, an understanding of their mechanism of action and pharmacologic characteristics is crucial to maximize their effectiveness while minimizing possible untoward effects. The clinician must evaluate potential risks and benefits as these substances come to market without definitive answers being available as to their long-term effects.
Usala
A L
AL
Department of Pediatrics, Saint Luke's Hospital, Cleveland, Ohio.
Blumer
J L
JL
D002648:Child; D002675:Child, Preschool; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D006130:Growth Disorders / Q000188:drug therapy*; D013006:Growth Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007328:Insulin / Q000494:pharmacology; D010900:Pituitary Diseases / Q000188:drug therapy*; D010906:Pituitary Hormone-Releasing Hormones / Q000627:therapeutic use; D011388:Prolactin / Q000627:therapeutic use; D011629:Puberty, Precocious / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013973:Thyrotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D014667:Vasopressins / Q000627:therapeutic use
D006728:Hormones; D007328:Insulin; D010906:Pituitary Hormone-Releasing Hormones; D011994:Recombinant Proteins; D014667:Vasopressins; D013004:Somatostatin; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D013006:Growth Hormone